Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Phase 2

Terminated

• Conditions: Hip Fracture

• Registration Number: NCT00128115
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this study is to demonstrate an improvement in physical functional recovery, following administration of Drug for 24 weeks, in patients who have recently experienced a hip fracture. This study will also evaluate the safety and tolerability of Drug.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-08-05
• Study First Submitted QC: 2005-08-08
• Study First Posted: 2005-08-09
• Study Start: 2005-09
• Primary Completion: 2007-08
• Study Completion: 2007-08
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-19
• Last Update Posted: 2016-01-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

• Patient has had surgery for a unilateral hip fracture, and is considered to be partially or fully weight bearing after the surgery
• Surgical repair of the fracture has occurred no more than 4 days post hip fracture
• Prior to starting the study medication, the patient is enrolled in a rehabilitation program (as an in-patient or as an out-patient)
• Patient is judged to have been able to ambulate independently at home prior to their hip fracture (able to walk indoors in a familiar setting with little or no aid from another person)

Exclusion Criteria

• Patient has an unstable medical condition

• Patient has a hip fracture that is due to bone pathology other than osteoporosis (e.g., malignancy, or Paget's Disease), or major trauma (e.g. motor vehicle accident).

• Patient has Type I diabetes

• Patient has Type II diabetes with any of conditions;

  1. Patient is currently taking more than one anti-hyperglycemic agent, or is taking a single combination anti-hyperglycemic drug containing more than one anti-hyperglycemic medication
  2. Patient is currently receiving insulin. Note: A short-term course of insulin required for glycemic control post hip fracture surgery is not exclusionary
  3. Patient has diabetic retinopathy
  4. Patient is unwilling or unable to monitor glucose at home

• Patient has been diagnosed with any neuromuscular or neurological disease causing muscle weakness

• Patient has cancer, or had a diagnosis of any malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or adequately treated in situ cervical cancer

• Patient has active carpal tunnel syndrome

• Patient was living in a nursing home prior to the hip fracture (Note: - Patients who were living in an assisted-living facility prior to the hip fracture are eligible for enrollment)

• Patient was permanently wheelchair bound prior to the hip fracture

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Proprietary Information - Exploratory (Non-Confirmatory) Trial

Secondary Outcome Measures

Name	Time	Method
Proprietary Information - Exploratory (Non-Confirmatory) Trial

Trial Locations

Locations (5)

MSD (Norge) AS; 🇳🇴 Drammen, Norway

Merck Sharp & Dohme (Sweden) AB; 🇸🇪 Sollentuna, Sweden

Msd Sharp & Dohme Gmbh; 🇩🇪 Haar, Germany

Merck Sharp & Dohme De Espana, S.A.E.; 🇪🇸 Madrid, Spain

Merch Sharp & Dohme Ltd.; 🇬🇧 Hoddesdon, Hertfordshire, United Kingdom